Quarles L D, Rutsky E A, Rostand S G
Am J Kidney Dis. 1985 Dec;6(6):412-9. doi: 10.1016/s0272-6386(85)80104-9.
Staphylococcus aureus bacteremia occurred 96 times in 58 of 671 patients on chronic hemodialysis during a nine-year period. Seventy-one instances of bacteremia originated in the vascular access site and resulted in the loss of the access device in 45 episodes. The overall mortality was 8%, and the incidence of infective endocarditis was 4%. Death occurred more often when bacteremia arose from an identifiable site other than the vascular access device (P less than .02). Patients who developed one or more metastatic foci of infection had a higher incidence of primary treatment failure (P less than .001) and a higher mortality (P less than .001) than did those with no metastatic infection. Although meaningful comparisons of differing antibiotic regimens could not be made, patients receiving antibiotic therapy for 28 days or longer relapsed less frequently (P less than .05). These data suggest that chronic hemodialysis patients with S aureus bacteremia have a relatively low mortality and a low risk of infective endocarditis. Antibiotic treatment, however, should be given for at least 28 days in order to minimize the risk of relapse.
在九年期间,671例慢性血液透析患者中有58例发生了96次金黄色葡萄球菌菌血症。71例菌血症起源于血管通路部位,其中45例导致血管通路装置丢失。总体死亡率为8%,感染性心内膜炎的发生率为4%。当菌血症起源于血管通路装置以外的可识别部位时,死亡更常发生(P<0.02)。发生一个或多个感染转移灶的患者,其初始治疗失败的发生率较高(P<0.001),死亡率也较高(P<0.001),高于无转移性感染的患者。虽然无法对不同抗生素治疗方案进行有意义的比较,但接受抗生素治疗28天或更长时间的患者复发频率较低(P<0.05)。这些数据表明,患有金黄色葡萄球菌菌血症的慢性血液透析患者死亡率相对较低,感染性心内膜炎风险较低。然而,抗生素治疗应至少持续28天,以尽量降低复发风险。